Q3 2025 Dare Bioscience Inc Earnings Call Transcript

Nov 13, 2025 / 09:30 PM GMT

Release Date Price: $1.89 (-4.55%)

Transcript 10-Q8-K

Key Points

Positve

Dare Bioscience Inc (DARE) is on track to launch its sildenafil cream through a 503B outsourcing facility by the end of the year, marking a significant milestone in women's sexual health.
The company is advancing a differentiated clinical pipeline with grant-funded programs targeting significant unmet needs, including contraception and HPV infection.
Dare Bioscience Inc (DARE) has secured approximately $18.7 million in net proceeds from sales of common stock and $7.3 million in grant payments, strengthening its financial position.
The company is leveraging strategic collaborations with public funders and foundations to advance its portfolio while maintaining disciplined capital allocation.
Dare Bioscience Inc (DARE) is preparing to expand its commercial portfolio with products like Dare to Restore vaginal probiotics and Dare to Reclaim hormone therapy, aiming for market availability in early 2026 and 2027, respectively.

Negative

The company faces regulatory challenges, as it continues discussions with the FDA to define acceptable endpoints for future FDA registration paths.
Dare Bioscience Inc (DARE) is subject to 'baby shelf' limitations, restricting its ability to utilize an ATM for additional capital.
The company's R&D expenses decreased by 56% year-over-year, primarily due to non-dilutive funding, which may indicate a reliance on external funding sources.
The anticipated availability of Dare to Reclaim hormone therapy is not until early 2027, which may delay potential revenue generation from this product.
Dare Bioscience Inc (DARE) is operating in a market that has historically been underfunded and underserved, which could pose challenges in gaining market traction and investor confidence.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

DARE.OQ - Dare Bioscience Inc
Q3 2025 Dare Bioscience Inc Earnings Call
Nov 13, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the conference call hosted by Dare Bioscience to review the company's 3rd quarter 2025 financial results and to provide a business update. This call is being recorded. My name is Jerko, and I will be your operator today. With us today from Dare are Sabrina Martucci Johnson, President and Chief Executive Officer, and Mardi Herring Leighton, Chief Accounting Officer. Ms. Herring Leighton, please proceed.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon and welcome to the DAA Bioscience Financial Results and Business update call for the quarter ended September

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.